Drugs News and Research

RSS

Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 clinical program for Zerenex(TM) (ferric citrate), its iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD).

6 Jan 2010

Opinions: U.S. medical emergency response; micronutrients; rotavirus vaccine; antibiotic development

"[D]espite the tireless efforts of public health and health-care workers, America's experience with H1N1 shows that the nation is not prepared to deal with a flu pandemic," former Democratic Senator Bob Graham and former Republican Senator Jim Talent write in Washington Post opinion piece that examines U.S. preparedness for medical emergencies. The writers chaired the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism.

6 Jan 2010

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway.

6 Jan 2010

Scott & White's CRI launches two clinical trials targeting cancers

Scott & White's Cancer Research Institute (CRI) has launched two clinical trials targeting cancers that affect both adults and children.

6 Jan 2010

Animal experiments show old antidepressant may reverse heart failure

A team of Johns Hopkins and other researchers have found in animal experiments that an antidepressant developed over 40 years ago can blunt and even reverse the muscle enlargement and weakened pumping function associated with heart failure.

6 Jan 2010

New research may yield more effective treatment for childhood leukemia

A team of Israeli scientists at the Sheba Medical Center's Research Center for Leukemia and Childhood Malignancies has discovered a method for developing a more effective and less perilous treatment for those suffering from childhood leukemia, the most common cancer in children.

6 Jan 2010

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.

6 Jan 2010

Preclinical data of Geron's telomerase inhibitor drug published

Geron Corporation today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor size in xenograft models of glioblastoma, and inhibited the activity of glioblastoma stem cells in culture.

6 Jan 2010

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody1 drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

6 Jan 2010

Most of world's 13m preterm births occur in Africa, Asia

The "vast majority" of the world's 13 million preterm births each year occur in developing countries where the babies' "chances of survivals are low," according to an article published Monday in the January issue of the Bulletin of the World Health Organization, Reuters reports.

6 Jan 2010

Findings reveals 'limpet-like' proteins can play a key role in DNA repair

UK scientists have found that a crafty family of 'limpet-like' proteins can play a crucial role in repairing DNA damage - according to two research papers published in Nature today (Wednesday). These findings could pave the way to the design of new anti-cancer drugs which target this process.

6 Jan 2010

H1N1 flu vaccine now available at CVS/pharmacy locations throughout California

CVS/pharmacy announced today that it has expanded the availability of H1N1 flu vaccine to more than 220 stores throughout the State of California.

6 Jan 2010

First Edition: January 5, 2010

Today's headlines focus on the Democratic plans to advance the health bill compromise process and the latest on the nation's health spending.

5 Jan 2010

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

Despite economic downturn, Russia still represents a promising healthcare market

Despite uncertain economic environment, Russia still represents a promising healthcare market with strong potential for further growth.

5 Jan 2010

Formatech selects ViroMed’s VM206 for Fillanthropy Program

Today, Formatech has selected the next candidate for its Fillanthropy Program: ViroMed’s VM206 therapeutic cancer vaccine. Under the Fillanthropy Program, Formatech will donate the services required to aseptically fill and finish one lot of the vaccine to support ViroMed’s upcoming clinical trials.

5 Jan 2010

CRT&T presents unique approach to solve issues presented to pharmaceutical executives

The Clinical Research Trends and Technology Forum (CRT&T) presents a unique approach to solving the issues presented to pharmaceutical executives. CRT&T blends educational keynotes and roundtables focusing on standards of care, quality processes and workflow with exposure to the newest and most innovative technologies on the market through one-on-one business meetings and networking events.

5 Jan 2010

Physicians fail to provide pain treatment for fear of prescription drug abuse

Millions of Americans with significant or chronic pain associated with their medical problems are being under-treated as physicians increasingly fail to provide comprehensive pain treatment - either due to inadequate training, personal biases or fear of prescription drug abuse.

5 Jan 2010

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body's sticky and viscous mucus secretions to deliver a sustained-release medication cargo.

5 Jan 2010

"Nanoworms" and doxorubicin loaded hollow nanoparticles to fight cancer

A team of researchers in California and Massachusetts has developed a "cocktail" of different nanometer-sized particles that work in concert within the bloodstream to locate, adhere to and kill cancerous tumors.

5 Jan 2010